LadRx CorpOTCQB:LADX
- LAST PRICE2.2300
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close2.1400 / 2.2300
- Day Range
- 52 Week Range
- Volume431
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LADX |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LadRx Corp | 1.0M | 3.8x | --- |
GlobeStar Therapeutics Corp | 1.0M | -0.4x | --- |
Capstone Holding Corp | 819.6K | -0.8x | --- |
Agentix Corp | 1.3M | -1.3x | --- |
Evelo Biosciences Inc | 804.6K | 0.0x | --- |
Regenicin Inc | 767.4K | -0.8x | --- |
Company Information
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an organic backbone that is attached to a chemo toxic agent. The LADR backbone is to first target and deliver the chemo toxic agent to the tumor environment, and then to release the chemo toxic agent within the tumor. The LADR Technology offers the opportunity for multiple pipeline drugs. The LADR development efforts are focused on two classes of ultra-high potency albumin-binding drugs. These LADR-based drugs, LADRs 7, 8, 9, and 10, combine the proprietary LADR backbone with derivatives of the auristatin and maytansinoid drug classes.
Contact Information
- Headquarters
- 11726 San Vicente Boulevard, Suite 650LOS ANGELES, CA, United States 90049
- Phone
- 310-826-5648
- Fax
- 310-826-6139
Executives
- Non-Executive Chairman of the Board, Independent Director
- Jennifer Simpson
- Chief Executive Officer
- Stephen Snowdy
- Chief Financial Officer, Senior Vice President, Treasurer
- John Caloz
- Independent Director
- Joel Caldwell
- Independent Director
- Cary Claiborne
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 495.1K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.67 |
EPS | $0.59 |
Book Value | $0.22 |
P/E Ratio | 3.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | 3.2x |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
